A Phase IIb, open label, sequential cohort study comparing KappaMab alone to KappaMab in combination with lenalidomide and low dose dexamethasone (MRd) in Relapsed Refractory Multiple Myeloma

Category Primary study
Registry of TrialsAustralian New Zealand Clinical Trials Register
Year 2016
This article has no abstract
Epistemonikos ID: 9873e63d23e87f23940429402ca72123d75552c3
First added on: Feb 23, 2025